Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Non-pegylated liposomal doxorubicin + trastuzumab + docetaxel
- Development stage
- Phase 2
- Lead developer
- Chiesi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
A combination regimen consisting of non-pegylated liposomal doxorubicin, trastuzumab, and docetaxel is used as first-line therapy in patients with metastatic breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2). Non-pegylated liposomal doxorubicin is an anthracycline antibiotic formulated in a liposome to reduce cardiotoxicity compared to conventional formulations. Trastuzumab is a monoclonal antibody targeting the HER2 receptor, inhibiting proliferation of tumor cells that overexpress this protein. Docetaxel is a taxane-class chemotherapeutic agent that promotes microtubule assembly and inhibits cell division. The combination leverages different mechanisms of action for synergistic antitumor activity while aiming to minimize overlapping toxicities, particularly cardiac toxicity associated with anthracyclines and trastuzumab. Clinical studies have shown promising response rates and manageable safety profiles for this regimen in HER2-positive metastatic breast cancer[8].
- Brand names
- Herceptin + Taxotere + Myocet
- Other names
- trastuzumab + docetaxel + liposomal doxorubicintrastuzumab/docetaxel/NPLD
02
Targets
TOP2A (DNA topoisomerase II)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on Non-pegylated liposomal doxorubicin + trastuzumab + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Non-pegylated liposomal doxorubicin + trastuzumab + docetaxel.